Herclon 440 Mg contains trastuzumab and is used to treat HER2-positive breast cancer. It blocks the HER2 receptor, slowing down the growth of cancer cells and promoting apoptosis.
Herclon Features:
• Targeted therapy for HER2-positive breast cancer.
• Administered through intravenous infusion by medical professionals.
• Used in combination with other treatments as part of a comprehensive approach.
• Requires careful monitoring and management of potential side effects.
Copyright © 2024 Shivrupesh Pharma Private Limited All Rights Reserved.